Literature DB >> 1607911

Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery .

P G Gill1, J W Denham, G G Jamieson, P G Devitt, E Yeoh, C Olweny.   

Abstract

PURPOSE: The records of patients with esophageal cancer who were treated with a combined modality therapy were reviewed to determine the effects of simultaneously administered chemotherapy and radiotherapy (RT) at sites of recurrence and the relationship between treatment outcome and clinicopathologic variables. PATIENTS AND METHODS: One hundred seventeen patients were treated with fluorouracil (800 mg/m2) [corrected] and cisplatin (80 mg/m2) combined with either 36 Gy (36 patients) or 54 to 60 Gy (35 patients) of RT as sole therapy. Forty-six patients underwent surgery after they had received chemotherapy and 36 Gy of RT as initial treatment. Patients with either squamous cell cancer (SCC) or adenocarcinoma were included.
RESULTS: Complete endoscopic regression after an initial 36 Gy of RT and chemotherapy occurred in more than 50% of patients and in both tumor types. Relief of dysphagia accompanied tumor regression. Forty-two tumors were resected, and 11 showed a complete histologic response. Significant associations were demonstrated between enhanced survival and a diagnosis of SCC, a complete endoscopic response to initial chemotherapy and RT, and a tumor length of less than 5 cm. Multivariate analyses suggested that tumor length and complete endoscopic response were independent prognostic variables. The survival rate of patients treated by resection or radical-dosage RT was not significantly different.
CONCLUSIONS: The relief of dysphagia demonstrates the palliative value of chemotherapy and RT in both tumor types. The similar survival rates of patients with SCC or adenocarcinoma treated either surgically or with high-dose combined therapy (54 to 60 Gy) emphasize the need to evaluate the role of surgery and combined treatment in randomized studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607911     DOI: 10.1200/JCO.1992.10.7.1037

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.

Authors:  H Sekiguchi; S Akiyama; M Fujiwara; H Nakamura; K Kondo; Y Kasai; K Ito; J Sakamoto; H Takagi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Update: modern approaches to the treatment of localized esophageal cancer.

Authors:  James Welsh; Arya Amini; Anna Likhacheva; Jeremy Erasmus J; Daniel Gomez; Marta Davila; Reza J Mehran; Ritsuko Komaki; Zhongxing Liao; Wayne L Hofstetter; Jeffrey Lee H; Manoop S Bhutani; Jaffer A Ajani
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

3.  Combined radiochemotherapy for postoperative recurrence of oesophageal cancer.

Authors:  J L Raoul; E Le Prisé; B Meunier; V Julienne; P L Etienne; M Gosselin; B Launois
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

Review 4.  Adjuvant therapies for cancer of the thoracic esophagus.

Authors:  T Nishihira; T Nakano; S Mori
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

Review 5.  Combined modality therapy for esophageal cancer.

Authors:  Z Gamliel; M J Krasna
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 6.  Multimodal treatment for squamous cell esophageal cancer.

Authors:  U Fink; H J Stein; H Wilke; J D Roder; J R Siewert
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

7.  Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer.

Authors:  Urs Zingg; Jens Forberger; Branimir Rajcic; Christopher Langton; Glyn G Jamieson
Journal:  J Gastrointest Surg       Date:  2009-11-25       Impact factor: 3.452

8.  Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.

Authors:  M K Ferguson; L B Reeder; P C Hoffman; D J Haraf; L C Drinkard; E E Vokes
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

9.  Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer.

Authors:  Johannes B Roedl; Dushyant V Sahani; Rivka R Colen; Alan J Fischman; Peter R Mueller; Michael A Blake
Journal:  Eur Radiol       Date:  2008-07-24       Impact factor: 5.315

10.  Downstaging of esophageal cancer after preoperative radiation and chemotherapy.

Authors:  S B Vogel; W M Mendenhall; M D Sombeck; R Marsh; E R Woodward
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.